[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis

Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis

[18F]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene ([18F]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish [18F]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of [18F]FT8 PET imaging in human subjects.

Study Overview

• Status: Recruiting
• Conditions: Amyloidosis; Healthy Subjects; Amyloid; Cardiac Amyloidosis
• Intervention / Treatment: Diagnostic test: [18F]FT8

Detailed Description

Subjects will undergo [18F]FT8 PET/CT scans for safety and diagnostic efficacy evaluation. Organ uptake will be quantified using the standard uptake value (SUV). Clinical assessments and laboratory tests, including baseline information collection, physical examination, cardiac function assessment, and hepatic and renal function tests, will be conducted before and after the scan.

• Study Type: Observational
• Enrollment (Estimated): 25

Contacts and Locations

• Study Contact: Name: Haonan Yu; Phone Number: +8613821000597; Email: dreamadam@126.com

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China, 230000
      • Recruiting
      • The First Affiliated Hospital of University of Science and Technology of China
      • Contact: Qiang Xie; Phone Number: +8613721108043; Email: ahxq1980@163.com
  • Tianjin Municipality
    • Tianjin, Tianjin Municipality, China, 350005
      • Recruiting
      • Tianjin Medical University General Hospital
      • Contact: Haonan Yu; Phone Number: +8613821000597; Email: dreamadam@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Healthy volunteers and patients with confirmed or suspected systemic or cardiac amyloidosis, including cases secondary to hematologic disorders or genetic diseases.

Description

1. Subject Recruitment Participants will be recruited from outpatients and/or inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.
2. Amyloidosis Patients:

2.1 Inclusion Criteria:

Subjects must meet all of the following criteria:

1. Adult patients (age ≥ 18 years);
2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.
3. Scheduled to undergo a clinical Pan-Amyloid PET/CT scan as part of standard care or clinical evaluation.
4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria

Subjects will be excluded based on any of the following:

1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.
2. Pregnancy or breastfeeding.
3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.

3. Healthy Volunteers: 3.1 Inclusion Criteria:

Subjects must meet all of the following criteria:

1. Adult subjects (age ≥ 18 years);
2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).
3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:

Subjects will be excluded based on any of the following:

1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.
2. Pregnancy or breastfeeding.
3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy participants; Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of [18F]FT8 followed by a PET/CT scan.	Diagnostic test: [18F]FT8; Each subject will receive a single intravenous injection of [18F]FT8 and will undergo PET imaging at a specified time.
Amyloidosis Patients; Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of [18F]FT8, followed by a PET/CT scan.	Diagnostic test: [18F]FT8; Each subject will receive a single intravenous injection of [18F]FT8 and will undergo PET imaging at a specified time.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The safety assessment	The incidence of adverse events assessed by the investigator as related to the [18F]FT8 injection. Systematically collect and assess all adverse events within 7 days post-injection through physical examinations, vital signs monitoring, clinical laboratory tests (complete blood count, hepatic and renal function). All events will be graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.	From time of injection up to 7 days post-injection
[18F]FT8 Organ Uptake measured by Standardized Uptake Value (SUV)	Quantification of [18F]FT8 uptake in major organs (e.g., heart, liver, kidneys) using the Standardized Uptake Value (SUV). This measurement will be performed on the PET/CT scans acquired at a specified time. The outcome will be reported as the SUV for each organ in both amyloidosis patients and control subjects.	At the time of the single [18F]FT8 PET/CT scan (Day 1)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Biodistribution of [18F]FT8 in subjects	Semi-quantitatively evaluate the tracer's uptake in the interest organs (including heart, liver, kidneys, lungs, brain, bones, thyroid, blood pool, and other related organs) by measuring the Standard Uptake Value (SUV).	At the time of the single [18F]FT8 PET/CT scan (Day 1)
Radiation Dosimetry	Calculate the effective radiation dose (mSv) to various human organs and the whole body.	At the time of the single [18F]FT8 PET/CT scan (Day 1)

Collaborators and Investigators

• Sponsor: Tianjin Medical University
• Collaborators: Tianjin Medical University General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 21, 2025
• Primary Completion (Estimated): July 20, 2028
• Study Completion (Estimated): December 20, 2028

Study Registration Dates

• First Submitted: November 13, 2025
• First Submitted That Met QC Criteria: November 15, 2025
• First Posted (Actual): November 18, 2025

Study Record Updates

• Last Update Posted (Actual): November 18, 2025
• Last Update Submitted That Met QC Criteria: November 15, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: PET/CT; Cardiac amyloidosis; immunoglobulin light chain
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neuromuscular Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Peripheral Nervous System Diseases; Neurocognitive Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Heredodegenerative Disorders, Nervous System; Proteostasis Deficiencies; Amyloid Neuropathies; Amyloidosis, Familial; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Alzheimer Disease; Amyloidosis; Amyloid Neuropathies, Familial
• Other Study ID Numbers: TJMUGH-12

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No